123 related articles for article (PubMed ID: 27746118)
21. Establishment and characterization of cell lines from chromosomal instable colorectal cancer.
Maletzki C; Gock M; Randow M; Klar E; Huehns M; Prall F; Linnebacher M
World J Gastroenterol; 2015 Jan; 21(1):164-76. PubMed ID: 25574089
[TBL] [Abstract][Full Text] [Related]
22. miR-760 mediates chemoresistance through inhibition of epithelial mesenchymal transition in breast cancer cells.
Hu SH; Wang CH; Huang ZJ; Liu F; Xu CW; Li XL; Chen GQ
Eur Rev Med Pharmacol Sci; 2016 Dec; 20(23):5002-5008. PubMed ID: 27981531
[TBL] [Abstract][Full Text] [Related]
23. The involvement of epithelial-to-mesenchymal transition in doxorubicin resistance: Possible molecular targets.
Mirzaei S; Abadi AJ; Gholami MH; Hashemi F; Zabolian A; Hushmandi K; Zarrabi A; Entezari M; Aref AR; Khan H; Ashrafizadeh M; Samarghandian S
Eur J Pharmacol; 2021 Oct; 908():174344. PubMed ID: 34270987
[TBL] [Abstract][Full Text] [Related]
24. A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance.
Bidwell GL; Davis AN; Fokt I; Priebe W; Raucher D
Invest New Drugs; 2007 Aug; 25(4):313-26. PubMed ID: 17483874
[TBL] [Abstract][Full Text] [Related]
25. Development and characterization of P-glycoprotein 1 (Pgp1, ABCB1)-mediated doxorubicin-resistant PLHC-1 hepatoma fish cell line.
Zaja R; Caminada D; Loncar J; Fent K; Smital T
Toxicol Appl Pharmacol; 2008 Mar; 227(2):207-18. PubMed ID: 18076962
[TBL] [Abstract][Full Text] [Related]
26. siRNA Targeting of MDR1 Reverses Multidrug Resistance in a Nude Mouse Model of Doxorubicin-resistant Human Hepatocellular Carcinoma.
Yang H; Ding R; Tong Z; Huang J; Shen L; Sun YU; Liao J; Yang Z; Hoffman RM; Wang C; Meng X
Anticancer Res; 2016 Jun; 36(6):2675-82. PubMed ID: 27272776
[TBL] [Abstract][Full Text] [Related]
27. cDNA microarray analysis of multidrug resistance: doxorubicin selection produces multiple defects in apoptosis signaling pathways.
Watts GS; Futscher BW; Isett R; Gleason-Guzman M; Kunkel MW; Salmon SE
J Pharmacol Exp Ther; 2001 Nov; 299(2):434-41. PubMed ID: 11602652
[TBL] [Abstract][Full Text] [Related]
28. Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines.
Januchowski R; Sterzyńska K; Zaorska K; Sosińska P; Klejewski A; Brązert M; Nowicki M; Zabel M
J Ovarian Res; 2016 Oct; 9(1):65. PubMed ID: 27756418
[TBL] [Abstract][Full Text] [Related]
29. Genomic-directed targeted therapy increases endometrial cancer cell sensitivity to doxorubicin.
Indermaur MD; Xiong Y; Kamath SG; Boren T; Hakam A; Wenham RM; Apte SM; Lancaster JM
Am J Obstet Gynecol; 2010 Aug; 203(2):158.e1-40. PubMed ID: 20444440
[TBL] [Abstract][Full Text] [Related]
30. Modulation of DNA methylation levels sensitizes doxorubicin-resistant breast adenocarcinoma cells to radiation-induced apoptosis.
Luzhna L; Kovalchuk O
Biochem Biophys Res Commun; 2010 Feb; 392(2):113-7. PubMed ID: 20034463
[TBL] [Abstract][Full Text] [Related]
31. Vimentin silencing effect on invasive and migration characteristics of doxorubicin resistant MCF-7 cells.
Tezcan O; Gündüz U
Biomed Pharmacother; 2014 Apr; 68(3):357-64. PubMed ID: 24612689
[TBL] [Abstract][Full Text] [Related]
32. PGRMC1 contributes to doxorubicin-induced chemoresistance in MES-SA uterine sarcoma.
Lin ST; May EW; Chang JF; Hu RY; Wang LH; Chan HL
Cell Mol Life Sci; 2015 Jun; 72(12):2395-409. PubMed ID: 25596698
[TBL] [Abstract][Full Text] [Related]
33. Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.
Mamot C; Ritschard R; Wicki A; Küng W; Schuller J; Herrmann R; Rochlitz C
J Drug Target; 2012 Jun; 20(5):422-32. PubMed ID: 22519893
[TBL] [Abstract][Full Text] [Related]
34. Up-Regulation of Carbonyl Reductase 1 Renders Development of Doxorubicin Resistance in Human Gastrointestinal Cancers.
Matsunaga T; Kezuka C; Morikawa Y; Suzuki A; Endo S; Iguchi K; Miura T; Nishinaka T; Terada T; El-Kabbani O; Hara A; Ikari A
Biol Pharm Bull; 2015; 38(9):1309-19. PubMed ID: 26328486
[TBL] [Abstract][Full Text] [Related]
35. Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance.
Veitch ZW; Guo B; Hembruff SL; Bewick AJ; Heibein AD; Eng J; Cull S; Maclean DA; Parissenti AM
Pharmacogenet Genomics; 2009 Jun; 19(6):477-88. PubMed ID: 19440163
[TBL] [Abstract][Full Text] [Related]
36. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
[TBL] [Abstract][Full Text] [Related]
37. LGR5 Is a Gastric Cancer Stem Cell Marker Associated with Stemness and the EMT Signature Genes NANOG, NANOGP8, PRRX1, TWIST1, and BMI1.
Wang B; Chen Q; Cao Y; Ma X; Yin C; Jia Y; Zang A; Fan W
PLoS One; 2016; 11(12):e0168904. PubMed ID: 28033430
[TBL] [Abstract][Full Text] [Related]
38. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2.
Liao H; Bai Y; Qiu S; Zheng L; Huang L; Liu T; Wang X; Liu Y; Xu N; Yan X; Guo H
Oncotarget; 2015 Apr; 6(11):8914-28. PubMed ID: 25871397
[TBL] [Abstract][Full Text] [Related]
39. Molecular iodine impairs chemoresistance mechanisms, enhances doxorubicin retention and induces downregulation of the CD44+/CD24+ and E-cadherin+/vimentin+ subpopulations in MCF-7 cells resistant to low doses of doxorubicin.
Bontempo A; Ugalde-Villanueva B; Delgado-González E; Rodríguez ÁL; Aceves C
Oncol Rep; 2017 Nov; 38(5):2867-2876. PubMed ID: 28901484
[TBL] [Abstract][Full Text] [Related]
40. Fabrication of doxorubicin nanoparticles by controlled antisolvent precipitation for enhanced intracellular delivery.
Tam YT; To KK; Chow AH
Colloids Surf B Biointerfaces; 2016 Mar; 139():249-58. PubMed ID: 26724466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
